Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 25;2(10):100225. doi: 10.1016/j.jtocrr.2021.100225

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the International Association for the Study of Lung Cancer.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Kaplan-Meier analysis of overall survival (A) in the intention-to-treat population and (B) in key patient subgroups and progression-free survival assessed by BICR per RECIST version 1.1 (C) in the intention-to-treat population and (D) in key patient subgroups. Patients with tumors who were not assessable for PD-L1 TPS were not included in the relevant subgroup analyses. ∗Data not presented for subgroups of “Female” (n = 6) and for patients with brain metastasis at baseline (n = 4) owing to very few patients which precludes any meaningful analysis. BICR, blinded independent central review; Chemo, chemotherapy; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; pembro, pembrolizumab; NR, not reached; OS, overall survival; PD-L1, programmed death-ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors; TPS, tumor proportion score.

Kaplan-Meier analysis of overall survival (A) in the intention-to-treat population and (B) in key patient subgroups and progression-free survival assessed by BICR per RECIST version 1.1 (C) in the intention-to-treat population and (D) in key patient subgroups. Patients with tumors who were not assessable for PD-L1 TPS were not included in the relevant subgroup analyses. ∗Data not presented for subgroups of “Female” (n = 6) and for patients with brain metastasis at baseline (n = 4) owing to very few patients which precludes any meaningful analysis. BICR, blinded independent central review; Chemo, chemotherapy; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; pembro, pembrolizumab; NR, not reached; OS, overall survival; PD-L1, programmed death-ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors; TPS, tumor proportion score.